Its favorable efficacy-toxicity balance and convenient dosing support long-term use, particularly in younger or treatment-naïve patients. Future research should refine patient selection, explore predictive biomarkers, and define its role among disease-modifying agents capable of transforming PV into a chronic, potentially controllable disorder.

The most common adverse events were elevated liver enzymes (AST: 0.28; ALT: 0.32), influenza-like illness (0.11), and anemia (0.09), with unresolved heterogeneity in all outcomes.Ropeginterferon alfa-2b shows promising efficacy in achieving hematological and molecular responses in patients with PV. However, notable heterogeneity and safety concerns, particularly liver-related adverse effects, warrant further investigation in large-scale trials.

Our findings suggest that ropeginterferon alfa-2b could be considered as a second-line treatment option for patients with essential thrombocythaemia and leukocytosis.

The Janus kinase (JAK)/signal transducers and activators of transcription (STAT) pathway has recently been shown to play an important role in the pathogenesis of inflammation in TAFRO syndrome, and inhibitors of the JAK/STAT pathway may be effective as therapeutic agents for TAFRO syndrome. We herein report the successful treatment using combination therapy with ruxolitinib and ropeginterferon alfa-2b of a case of TAFRO-like syndrome with a long history of polycythemia vera with JAK2 V617F refractory to several treatments.

P2, N=11, Terminated, Mayo Clinic | Completed --> Terminated; Study drug became commercially available

P1, N=38, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Initiation date: Dec 2025 --> Aug 2025

Most effects of IFN-α on Jak2V617F cells were preserved in Jak2V617F;Stat1 -/- mice but to a moderate degree compared with Jak2V617F mice. Our study reveals essential roles of TYK2 for the preferential suppressive effect of IFN-α on Jak2V617F progenitors and HSCs.

P1, N=38, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Initiation date: Jul 2025 --> Dec 2025

P2, N=91, Active, not recruiting, PharmaEssentia | Trial primary completion date: Mar 2027 --> May 2025

P3, N=111, Active, not recruiting, PharmaEssentia | Trial completion date: Jul 2025 --> Jul 2027 | Trial primary completion date: Dec 2024 --> Jun 2025

P3, N=174, Active, not recruiting, PharmaEssentia | Trial completion date: Dec 2025 --> Aug 2029

P3, N=150, Recruiting, PharmaEssentia | Not yet recruiting --> Recruiting | Trial completion date: Apr 2028 --> Sep 2028 | Trial primary completion date: Mar 2027 --> Sep 2027